Research programme: small molecule therapeutics - Proximagen

Drug Profile

Research programme: small molecule therapeutics - Proximagen

Alternative Names: PAR-2 - Proximagen; SSAO inhibitor - Proximagen; TrkA - Proximagen

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cambridge Biotechnology
  • Developer Proximagen
  • Class Small molecules
  • Mechanism of Action AOC3 protein inhibitors; AOC3 protein modulators; PAR 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Atopic dermatitis; Cancer; Inflammatory pain; Irritable bowel syndrome; Ulcerative colitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top